Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 TNFSF13B [4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab [13] 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300
2 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim [35] 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
3 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
4 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
5 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
6 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
7 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
8 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
9 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine [2] 22, 296
10 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
11 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [2] 22, 296
12 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
13 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [2] 22, 296
14 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
15 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
16 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
17 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
18 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
19 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
20 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
21 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
22 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
23 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
24 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
25 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
26 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
27 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
28 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
29 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
30 NR3C1 [1] Neuroactive ligand-receptor interaction D00292 Dexamethasone [2] 296, 299
31 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [1] 296
32 NR3C1 [1] Neuroactive ligand-receptor interaction D00472 Prednisolone [3] 296, 299, 300
33 PPARA [10] PPAR signaling pathway, cAMP signaling pathway, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy D01366 Bezafibrate [7] 20, 93, 94, 160, 296, 316, 324
34 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
35 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00969 Meloxicam [4] 46, 49, 271, 296
36 SLC10A1 [2] Bile secretion, Hepatitis B D10951 Maralixibat [3] 296, 297, 338
37 SLC10A2 [1] Bile secretion D10951 Maralixibat [3] 296, 297, 338
38 SLC10A2 [1] Bile secretion D11716 Odevixibat [3] 296, 297, 338
39 MS4A1 [1] Hematopoietic cell lineage D02994 Rituximab [3] 296, 300, 331
40 KEAP1 [6] Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D03846 Dimethyl fumarate [5] 13, 49, 51, 86, 296
41 NR1H4 [1] Bile secretion D00734 Ursodeoxycholic acid [2] 296, 299
42 NR1H4 [1] Bile secretion D09360 Obeticholic acid [1] 296